Equities research analysts expect that Marrone Bio Innovations Inc (NASDAQ:MBII) will announce ($0.04) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Marrone Bio Innovations’ earnings, with the lowest EPS estimate coming in at ($0.05) and the highest estimate coming in at ($0.03). Marrone Bio Innovations also posted earnings per share of ($0.04) during the same quarter last year. The business is scheduled to issue its next earnings results on Tuesday, August 13th.
On average, analysts expect that Marrone Bio Innovations will report full year earnings of ($0.16) per share for the current year, with EPS estimates ranging from ($0.18) to ($0.14). For the next financial year, analysts expect that the firm will post earnings of ($0.13) per share, with EPS estimates ranging from ($0.15) to ($0.10). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Marrone Bio Innovations.
Marrone Bio Innovations (NASDAQ:MBII) last released its quarterly earnings data on Thursday, May 9th. The basic materials company reported ($0.04) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). Marrone Bio Innovations had a negative return on equity of 123.95% and a negative net margin of 82.82%. The business had revenue of $8.72 million for the quarter, compared to analysts’ expectations of $6.18 million.
Large investors have recently added to or reduced their stakes in the company. Paloma Partners Management Co bought a new position in shares of Marrone Bio Innovations during the 4th quarter valued at about $73,000. SG Americas Securities LLC bought a new position in shares of Marrone Bio Innovations during the 1st quarter valued at about $74,000. Rhumbline Advisers lifted its holdings in shares of Marrone Bio Innovations by 44.3% during the 4th quarter. Rhumbline Advisers now owns 68,021 shares of the basic materials company’s stock valued at $100,000 after purchasing an additional 20,882 shares in the last quarter. Spark Investment Management LLC lifted its holdings in shares of Marrone Bio Innovations by 47.5% during the 1st quarter. Spark Investment Management LLC now owns 95,000 shares of the basic materials company’s stock valued at $145,000 after purchasing an additional 30,600 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Marrone Bio Innovations by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 443,611 shares of the basic materials company’s stock valued at $652,000 after purchasing an additional 24,460 shares in the last quarter. Institutional investors and hedge funds own 42.04% of the company’s stock.
Shares of NASDAQ:MBII traded down $0.02 during trading on Friday, hitting $1.42. 246 shares of the company’s stock traded hands, compared to its average volume of 78,418. Marrone Bio Innovations has a 52 week low of $1.10 and a 52 week high of $2.18. The company has a current ratio of 1.94, a quick ratio of 1.47 and a debt-to-equity ratio of 2.47. The firm has a market cap of $159.44 million, a P/E ratio of -6.76 and a beta of -0.08. The firm has a 50-day simple moving average of $1.48.
Marrone Bio Innovations Company Profile
Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.
Featured Story: Trading Strategy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.